{'fraction_non_alphanumeric': 0.018487394957983194, 'fraction_numerical': 0.0, 'mean_word_length': 6.180722891566265, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

This review evaluated the benefits and harms of antiviral agents as pre-emptive treatment to prevent symptomatic cytomegalovirus (CMV) disease in all solid organ transplant recipients. Pre-emptive treatment is commenced when evidence of active CMV replication is found on routine surveillance. This review includes pre-emptive treatment versus placebo or treatment when symptomatic, pre-emptive treatment versus prophylaxis and different regimens of preemptive treatment.